Small Cap Feast

16th January 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 



Delistings:




Whats baking in the oven?

Potential Initial Public Offerings:

12 Jan—The London Tunnels PLC announces its intention to seek admission to the standard segment of the Official List and to trading on the Main Market of London Stock Exchange plc (Admission). The Company plans to restore, adaptively reuse and bring back to life the Kingsway Exchange Tunnels in Central London, originally built in the early 1940s, and designed to shelter people during the London Blitz. The Company has successfully raised approximately £10m from investors and aims to admit its Ordinary Shares at a price of £2.00 per share to the Main Market of the London Stock Exchange. The Company is expected to have a market capitalisation of approximately £123 million on Admission Expected Admission to take place in January 2024.


Reverse Takeovers:


Change of Market:


Banquet Buffet

Block Energy 1.05p £7.6m (BLOE.L)
The development and production company focused on Georgia, announces a study identifying a Carbon Capture and Storage (CCS) opportunity within the Company's Block XIB with the potential to support a major net-zero CO2 industrial hub. The reservoir scale storage is estimated at 256 million metric tonnes, equivalent to offsetting emissions from 55 million cars, and the basin scale at up to 8.7 gigatonnes, equivalent to offsetting emissions from Turkey for 20 years. The research suggests Block XIB is best suited to the Mineral Trapping (Mineralisation) method whereby CO2 is injected with water and mineralises as solid carbonates.

Bradda Head Lithium 1.65p £6.4m (BHL.L)
The North America-focused lithium development group, announces final results from core drilling at the San Domingo Central target area, Arizona, completed on 2 December 2023. Results from the San Domingo Central Target Area are highlighted by the following intervals: 7.28m at 1.27% Li2O in hole SD-DH23-069 from 27.43m depth at White Ridge, 5.18m of 0.88% Li2O in hole SD-DH23-072 at White Ridge and 5.06m @ 0.49% Li2O in hole SD-DH23-083 at Joker. Shallow lithium mineralised intercepts were encountered at the Central Target Area, with 90% of significant intercepts at <100m depth.

DP Poland 11p £78.4m (DPP.L)
The operator of Domino's pizza stores and restaurants across Poland and Croatia, announces a trading update for Q4 2023 and FY 2023. The Company expected FY 2023 Group System Sales of £46.0m and LFL System Sales in Poland increased by 27.5% in Q4 to the highest in the Company's history and by 19.7% for FY2023. The Company is EBITDA profitable since August and expected to be in line with market expectations for FY 2023 and holds cash at bank of £2.2m as at 31 December 2023 (£2.7m cash as at 30 June 2023). The Group finish the year with a store network that has been optimised, supporting higher LFL sales as well as growing our store count to 116 stores.

Equals Group 116p £217.6m (EQLS.L)
The fintech payments group focused on the Enterprise and SME marketplace, announces a trading update for the financial year ended 31 December 2023 (FY-23). Unaudited revenues for the year were £95.5m, up 37% (FY-22: £69.7m) with continued growth in Adjusted EBITDA. This robust trading has also resulted in approximately £18.3m of cash at bank at 31 December 2023. Revenue per working day increased by 36.4% over FY-23. The revenue growth continues to be driven by Solutions revenues augmented by B2B growth across other product lines. The Board expects the Group's FY-23 results to be in-line with current market expectations.

IQE 20.75p £199.5m (IQE.L)
The supplier of compound semiconductor wafer products and advanced material solutions, provides a trading update for the financial year ended 31 December 2023. Revenue for the period is expected to be at least £115m, reflecting over 20% increase from H1 to H2 2023, in line with previously issued guidance. The Group expects this to result in an adjusted EBITDA of at least £3m and a net debt position of c.£3m. The Group further announce the appointment of Jutta Meier to the Board as Chief Financial Officer effective from 22 January 2024. Jutta is an experienced finance executive who has held senior positions at global semiconductor companies for over 25 years. She joins IQE from Intel Corporation, where she served as a Senior Finance Director.

Kibo Energy* 0.039p £1.5m (KIBO.L)
The renewable energy-focused developer of sustainable energy solutions, provides an interim strategy update in relation to its development approach. Kibo's strategy revolves around its commitment to being a developer of sustainable clean energy solutions by integrating both established and cutting-edge technologies in renewable energy generation, waste-to-energy and energy storage. The primary focus is to deliver enduring, low- or zero-carbon energy-generation solutions across Southern Africa, the UK and Ireland. Operationally, the Company: is currently formulating a joint development agreement with a multinational food and beverage producer intended to be funded equally (i.e., 50-50) by Kibo and the Client. It has received conditional preliminary approval for development funding, subject to due diligence, from a prominent development banking institution in Southern Africa for one of the Company's existing waste-to-energy projects.

Northcoders Group 160p £12.8m (CODE.L)
A UK market technology training business, announces that it has successfully secured further funding from the Department for Education Skills Bootcamp Dynamic Purchasing System 2 bid (DPS). This new round of funding provides Northcoders with a further £10m to train individuals on the Northcoders market-leading bootcamp, deliverable over 18 months, and provides the Company with strong revenue visibility for FY-2024 and H1-2025. It also underpins an 18.6% increase in revenue per student.

N4 Pharma 1.08p £2.9m (N4P.L)
The pharmaceutical company developing Nuvec®, a delivery system for cancer treatments, gene therapy and vaccines, provides an update on its subsidiary, Nanogenics Limited. Nanogenics has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at Kings College, London. The work involves creating and testing a novel formulation containing Nanogenics' proprietary siRNA sequence to undertake a proof of concept in-vivo study, and that it can match the anti-fibrotic effect of current post surgical treatment using Mitomycin C, but without the cytotoxic side effects seen with this approach.

Ondine Biomedical 8.75p £19.8m (OBI.L)
A Canadian life sciences company announces the appointment of Joseph P. (JP) Errico as Chief Financial Officer. JP will be responsible for managing and developing Ondine's finance function, as well as managing the capital markets interface, participating in discussions with large health systems and customers. JP has successfully founded and sold (or taken public) several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore.

4Global 62.5p £16.5m (4GBL.L)
A UK-based data, services and software company focused on major sporting events and the promotion and measurement of physical activity, announces that it has been awarded two contracts in the Kingdom of Saudi Arabia (KSA) resulting in a combined value of over £800k. The initial award, with the client in KSA, has enlisted the services of 4GLOBAL to assess the value and operational viability of a number of sporting facilities in the area, and second award is with a new partner within the region. The majority of the work scheduled for completion within the current financial year.

16 January 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged
**** Potential means Intention to Float (ITF) has been announced, or it is a rumour

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram